Cocrystal Pharma (NASDAQ:COCP – Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.06), FiscalAI reports. The business had revenue of $0.10 million for the quarter, compared to analyst estimates of $0.10 million.
Cocrystal Pharma Trading Up 1.8%
COCP traded up $0.02 on Friday, reaching $1.12. The stock had a trading volume of 38,297 shares, compared to its average volume of 70,708. The business’s 50-day moving average price is $0.99 and its two-hundred day moving average price is $1.10. Cocrystal Pharma has a 12-month low of $0.76 and a 12-month high of $2.67. The company has a market cap of $15.44 million, a P/E ratio of -1.47 and a beta of 1.43.
Wall Street Analyst Weigh In
Separately, Weiss Ratings upgraded shares of Cocrystal Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 8th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has an average rating of “Sell”.
Institutional Trading of Cocrystal Pharma
A hedge fund recently bought a new stake in Cocrystal Pharma stock. DRW Securities LLC acquired a new position in shares of Cocrystal Pharma, Inc. (NASDAQ:COCP – Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 33,593 shares of the company’s stock, valued at approximately $33,000. DRW Securities LLC owned 0.24% of Cocrystal Pharma as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 6.72% of the company’s stock.
About Cocrystal Pharma
Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.
The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.
Read More
- Five stocks we like better than Cocrystal Pharma
- Is Best Buy the AI Winner Hiding in the Electronics Aisle?
- Applied Materials Beat Everything but Wall Street’s Expectations for Margins
- Back From Orbit, Intuitive Machines’ Share Price Enters the Buy Zone
- Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing
Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
